• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Increasing the Dose of Etanercept not Efficacious in Rheumatoid Arthritis

Increasing the Dose of Etanercept not Efficacious in Rheumatoid Arthritis

July 24, 2008 By Arthritis Center

Biochemical structure of etanercept
Figure: Biochemical Structure of Etanercept

Increasing the dose of infliximab and, in some cases, adalimumab can result in improved efficacy in RA patients with inadequate responses to initial dosing.  However, whether increasing the dose of etanercept can also result in clinical improvement has not been studied.  Here, Weinblatt et al (Arthritis Rheum 2008; 58: 1921) present results from a randomized clinical trial comparing etanercept 50 mg per week to etanercept 100 mg per week in RA patients who had failed to respond to etanercept 50 mg per week in combination with methotrexate.

The Methods and Results of this trial as published are identical to those presented at the 2007 American College of Rheumatology Annual Scientific Meeting.

Editorial Comment

Although with the same molecular targets, there are differences in the mechanism of action of the various TNF inhibitors.  These data suggest that there is indeed a ceiling effect of etanercept for efficacy in RA, but perhaps not for safety—as these data suggest, but do not prove, that the higher dose may be associated with an increased risk of serious adverse events.  Due to the relatively small sample size of the study, the small increase in efficacy associated with the higher dose of etanercept was not detected as statistically significant.  However, the small difference cannot be considered clinically meaningful, and the use of etanercept at this dose cannot be encouraged based on these small differences.  The ceiling effect for efficacy may not be exclusive to decoy receptors like etanercept, for although adalimumab, a monoclonal antibody that is mechanistically distinct from etanercept, is licensed for use weekly; whether increasing the dose in this manner is truly associated with efficacy benefit has recently been questioned.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy